Neurogene Inc. reported results
SEC 8-KRead source ↗
Neurogene Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 4 selling0 purchases and 17 sales by directors and officers, last 12 monthsInsider trades
- Funds60 adding, 35 cuttingOf 24 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 12% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Neurogene Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 79% and a beta of 1.6 against the S&P 500.
- Heavily shorted. 30.2% of the shares available to trade are sold short (13.3 days of average volume to cover).
Latest results
- Earnings per share
- -$1.53 against an average estimate of -$1.37: missed by 11.7%
- Share reaction
- +1.2% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
- Next report
- November 12, 2026; average EPS estimate -$1.45
Price chart
- 1 day-3.4%
- 1 week+13.0%
- 1 month+3.7%
- This year+29.2%
- 1 year-22.3%
- 5 years-82.8%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 11, 2026
- Next results (est.)
- November 12, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
No model value for Neurogene Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Neurogene Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.46 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Neurogene Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, before the open. Analysts expect revenue of $0 and EPS of −$1.45 (range −$1.59 to −$1.36) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$5.75 | −36% | — | 0% |
| Next | −$5.72 | +0% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +8.1% on 90 days ago. In the last 30 days, 1 analyst raised Neurogene Inc.'s forecast and 3 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$5.31 | −$5.46 |
| 60 days ago | −$5.66 | −$5.18 |
| 30 days ago | −$5.66 | −$5.18 |
| 7 days ago | −$5.75 | −$5.18 |
| Now | −$5.75 | −$5.72 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.37 | −$1.53 | −11.7% |
| Dec 2025 | −$1.24 | −$1.13 | +8.7% |
| Sept 2025 | −$1.09 | −$0.99 | +9.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 30.2% of tradable shares
- Days to cover
- 13.31 at average volume
- Short interest, 1 month
- +55% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 7.0% of shares
- Employees
- 131 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| NGNE | −66% | −89% | +90% | +18% | −10% | +29% |
| Industry peers (median) | −35% | −56% | −18% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| NGNE | 33% | 17% | 67% | 58% | 42% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| NGNE | −71% | −92% | −33% | −79% | −69% | −50% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 98% from February 9, 2017 to April 8, 2025. Getting back needed a 5284% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $16.37 – $42.84
- From 52-week high
- −37.9%
- vs 50-day average
- −12.7%
- vs 200-day average
- −4.5%
- Volatility (1 year)
- 79%
- Beta vs S&P 500
- 1.61
Share price after results
- Next day
- 5 up, 7 down typical move ±14.9%
- After a week
- 4 up, 8 down typical move ±15.2%
- After a month
- 5 up, 7 down typical move ±18.7%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 11, 2026 | +1.2% | −0.1% | −2.4% | −1.2% |
| May 12, 2026 | +5.6% | +0.4% | −13.0% | −6.1% |
| March 24, 2026 | +13.8% | +0.2% | +4.1% | +39.2% |
| November 13, 2025 | −26.7% | −1.7% | −34.4% | −34.8% |
| August 11, 2025 | −9.4% | +0.9% | −3.6% | −12.3% |
| May 9, 2025 | +18.0% | +3.2% | +19.9% | +43.9% |
| March 24, 2025 | −0.1% | +2.0% | −17.6% | +8.7% |
| November 18, 2024 | −50.1% | +0.8% | −35.3% | −36.9% |
| August 9, 2024 | −5.1% | +0.5% | −4.2% | +3.8% |
| May 10, 2024 | −7.7% | +0.1% | +0.3% | +12.0% |
| March 18, 2024 | +20.1% | +1.2% | +30.6% | −10.4% |
| November 14, 2022 | −21.3% | 0.0% | −16.5% | −14.8% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $544M
- Institutions reporting
- 112
- Shares held vs prior quarter
- ▲ 2.0%
- Positions opened / closed
- 22 / 4
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Samsara Biocapital, LLC | $54M | 1.7M | 9.9% | 0.0% |
| Casdin Capital, LLC | $48.6M | 1.5M | 8.9% | ▲ 8.8% |
| Redmile Group, LLC | $44.4M | 1.4M | 8.2% | ▼ 3.2% |
| RTW Investments, LP | $42.8M | 1.4M | 7.9% | 0.0% |
| Ecor1 Capital, LLC | $40M | 1.3M | 7.3% | 0.0% |
| Blackrock, Inc. | $33.3M | 1.1M | 6.1% | ▲ 5.3% |
| Baker Bros. Advisors LP | $31.2M | 992K | 5.7% | 0.0% |
| Balyasny Asset Management L.P. | $25.7M | 819K | 4.7% | ▲ 14.0% |
| Trails Edge Capital Partners, LP | $22.5M | 715K | 4.1% | ▼ 8.7% |
| Toronto Dominion Bank | $21.4M | 681K | 3.9% | 0.0% |
| Vanguard Capital Management LLC | $16.9M | 537K | 3.1% | ▲ 4.2% |
| Jennison Associates LLC | $16.3M | 519K | 3.0% | ▼ 1.7% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Neurogene Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.1M 17 trades by 4 insiders · 100% under pre-set plans
Net ▼ $1.1M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Cvijic Christine Mikail President and CFO | July 7, 2026 | Sell pre-set plan | 4,200 | $36.13 | $151,746 |
| Cvijic Christine Mikail President and CFO | July 6, 2026 | Sell pre-set plan | 600 | $36.02 | $21,612 |
| Cvijic Christine Mikail President and CFO | July 2, 2026 | Sell pre-set plan | 1,530 | $35.23 | $53,902 |
| Cvijic Christine Mikail President and CFO | July 2, 2026 | Sell pre-set plan | 2,531 | $34.58 | $87,522 |
| Cvijic Christine Mikail President and CFO | July 1, 2026 | Sell pre-set plan | 739 | $34.06 | $25,170 |
| Cvijic Christine Mikail President and CFO | May 6, 2026 | Sell pre-set plan | 4,800 | $30.07 | $144,336 |
| Cvijic Christine Mikail President and CFO | May 6, 2026 | Sell pre-set plan | 4,800 | $32.44 | $155,712 |
| Jordan Julie Chief Medical Officer | March 26, 2026 | Sell pre-set plan | 828 | $21.89 | $18,125 |
| Mcminn Rachel Chief Executive Officer | March 26, 2026 | Sell pre-set plan | 3,352 | $22.07 | $73,979 |
| Cvijic Christine Mikail President and CFO | March 26, 2026 | Sell pre-set plan | 2,558 | $21.62 | $55,304 |
| Cvijic Christine Mikail President and CFO | March 13, 2026 | Sell pre-set plan | 2,387 | $20.42 | $48,743 |
| Cvijic Christine Mikail President and CFO | March 13, 2026 | Sell pre-set plan | 1,395 | $21.25 | $29,644 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
- August 11, 2026
- May 12, 2026
- March 24, 2026
- November 13, 2025
- August 11, 2025
- May 9, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Neurogene Inc. in brief
- What does Neurogene Inc. do?
- Neurogene Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Neurogene Inc.'s stock ticker?
- Neurogene Inc. trades under the ticker NGNE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Neurogene Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Samsara Biocapital, LLC, Casdin Capital, LLC and Redmile Group, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Neurogene Inc. stock?
- Over the last 12 months, Neurogene Inc.'s directors and officers reported 0 open-market purchases and 17 sales on Form 4. The insider trading page charts every trade.
- When is Neurogene Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Neurogene Inc. announces its own schedule.
Follow research on Neurogene Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.